COVID-19 in Adults With Hypertrophic Cardiomyopathy

Background: Individuals with cardiovascular disease are considered high risk for severe COVID-19. However, the clinical impact of COVID-19 in patients with hypertrophic cardiomyopathy (HCM) is unknown. The purpose of this study was to describe the clinical course and outcomes of COVID-19 in patients...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Milla E. Arabadjian, Maria C. Reuter, Alexandra Stepanovic, Mark V. Sherrid, Daniele Massera
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	COVID-19 hypertrophic cardiomyopathy outcomes risk obesity Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/1fdcf6c83f2f4e2ebd253f9f5412a413
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1fdcf6c83f2f4e2ebd253f9f5412a413
record_format	dspace
spelling	oai:doaj.org-article:1fdcf6c83f2f4e2ebd253f9f5412a4132021-11-09T05:05:21ZCOVID-19 in Adults With Hypertrophic Cardiomyopathy2297-055X10.3389/fcvm.2021.745790https://doaj.org/article/1fdcf6c83f2f4e2ebd253f9f5412a4132021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fcvm.2021.745790/fullhttps://doaj.org/toc/2297-055XBackground: Individuals with cardiovascular disease are considered high risk for severe COVID-19. However, the clinical impact of COVID-19 in patients with hypertrophic cardiomyopathy (HCM) is unknown. The purpose of this study was to describe the clinical course and outcomes of COVID-19 in patients with HCM.Methods: This retrospective observational study included adults with HCM and positive PCR/antibody test for SARS-CoV-2 at a large urban hospital system in the New York from January, 2020 to January, 2021.Results: Seventy individuals were included, with a mean (SD) age of 60.1 (15.1) years, 39 (55.7%) of whom were male, and 42 (60%) white. Forty-five (65.3%) patients had obstructive HCM. Hypertension and obesity (BMI ≥ 30) were present in 45 (64.3%) and 37 (52.9%) patients, and the prevalence of atrial fibrillation, obstructive sleep apnea and diabetes was high. Common symptoms of COVID-19 were fever, cough, shortness of breath and fatigue, affecting 33 (47.1%), 33 (47.1%), 28 (40.0%), and 28 (40.0%) patients, respectively. Fourteen (20%) patients were hospitalized. The majority (45 [64.3%] patients) recovered without intervention. Two patients had non-fatal pulmonary embolisms, 1 had atrial fibrillation requiring electrical cardioversion and 1 had acute decompensated heart failure. Three (4.3%) patients required mechanical ventilation, two of whom died (case fatality rate 2.9%). A total of 15 (21.4%) patients were asymptomatic.Conclusions: Our data suggest that in this diverse and high-risk group of patients with HCM, established risk factors for severe COVID-19, such as obesity, may be more important drivers of morbidity and mortality than the presence of HCM alone.Milla E. ArabadjianMaria C. ReuterAlexandra StepanovicMark V. SherridDaniele MasseraFrontiers Media S.A.articleCOVID-19hypertrophic cardiomyopathyoutcomesriskobesityDiseases of the circulatory (Cardiovascular) systemRC666-701ENFrontiers in Cardiovascular Medicine, Vol 8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID-19 hypertrophic cardiomyopathy outcomes risk obesity Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	COVID-19 hypertrophic cardiomyopathy outcomes risk obesity Diseases of the circulatory (Cardiovascular) system RC666-701 Milla E. Arabadjian Maria C. Reuter Alexandra Stepanovic Mark V. Sherrid Daniele Massera COVID-19 in Adults With Hypertrophic Cardiomyopathy
description	Background: Individuals with cardiovascular disease are considered high risk for severe COVID-19. However, the clinical impact of COVID-19 in patients with hypertrophic cardiomyopathy (HCM) is unknown. The purpose of this study was to describe the clinical course and outcomes of COVID-19 in patients with HCM.Methods: This retrospective observational study included adults with HCM and positive PCR/antibody test for SARS-CoV-2 at a large urban hospital system in the New York from January, 2020 to January, 2021.Results: Seventy individuals were included, with a mean (SD) age of 60.1 (15.1) years, 39 (55.7%) of whom were male, and 42 (60%) white. Forty-five (65.3%) patients had obstructive HCM. Hypertension and obesity (BMI ≥ 30) were present in 45 (64.3%) and 37 (52.9%) patients, and the prevalence of atrial fibrillation, obstructive sleep apnea and diabetes was high. Common symptoms of COVID-19 were fever, cough, shortness of breath and fatigue, affecting 33 (47.1%), 33 (47.1%), 28 (40.0%), and 28 (40.0%) patients, respectively. Fourteen (20%) patients were hospitalized. The majority (45 [64.3%] patients) recovered without intervention. Two patients had non-fatal pulmonary embolisms, 1 had atrial fibrillation requiring electrical cardioversion and 1 had acute decompensated heart failure. Three (4.3%) patients required mechanical ventilation, two of whom died (case fatality rate 2.9%). A total of 15 (21.4%) patients were asymptomatic.Conclusions: Our data suggest that in this diverse and high-risk group of patients with HCM, established risk factors for severe COVID-19, such as obesity, may be more important drivers of morbidity and mortality than the presence of HCM alone.
format	article
author	Milla E. Arabadjian Maria C. Reuter Alexandra Stepanovic Mark V. Sherrid Daniele Massera
author_facet	Milla E. Arabadjian Maria C. Reuter Alexandra Stepanovic Mark V. Sherrid Daniele Massera
author_sort	Milla E. Arabadjian
title	COVID-19 in Adults With Hypertrophic Cardiomyopathy
title_short	COVID-19 in Adults With Hypertrophic Cardiomyopathy
title_full	COVID-19 in Adults With Hypertrophic Cardiomyopathy
title_fullStr	COVID-19 in Adults With Hypertrophic Cardiomyopathy
title_full_unstemmed	COVID-19 in Adults With Hypertrophic Cardiomyopathy
title_sort	covid-19 in adults with hypertrophic cardiomyopathy
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/1fdcf6c83f2f4e2ebd253f9f5412a413
work_keys_str_mv	AT millaearabadjian covid19inadultswithhypertrophiccardiomyopathy AT mariacreuter covid19inadultswithhypertrophiccardiomyopathy AT alexandrastepanovic covid19inadultswithhypertrophiccardiomyopathy AT markvsherrid covid19inadultswithhypertrophiccardiomyopathy AT danielemassera covid19inadultswithhypertrophiccardiomyopathy
_version_	1718441275608268800

COVID-19 in Adults With Hypertrophic Cardiomyopathy

Ejemplares similares